Recently, a reported study demonstrated a novel targeted therapeutic strategy for liver fibrosis using mesenchymal stromal cells (MSCs) engineered with a high-affinity peptide ligand (pPB) specific for the platelet-derived growth factor receptor beta (PDGFRβ), which is overexpressed on activated hepatic stellate cells (aHSCs). The gene discussed is PDGFRB; the disease is Hepatic fibrosis.